Secukinumab Treatment in Patients with Spondyloarthritis and Concomitant Demyelinating Disease: Rationale of IL-17 Inhibition and Clinical Outcome. acmcr [Internet]. 2022 Oct. 5 [cited 2026 Sep. 11];6(5):660-8. Available from: https://fortunejournals.org/ojs/index.php/acmcr/article/view/22670